SEARCH

SEARCH BY CITATION

References

  • 1
    Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 11811193.
  • 2
    Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
  • 3
    Kniepeiss D, Iberer F, Grasser B, Shaffellner S, Tschelliessnigg KH. Sirolimus and mycophenolate mofetil after liver transplantation. Transplant Int 2003; 16: 504509.
  • 4
    Bansabach CC, Wancio D, Sehgal SN. Sirolimus (rapamycin) inhibits mitogen-induced stimulation of protein synthesis in primary lymphocytes. Inflamm Res 1995; 44: S179.
  • 5
    Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Case report. Mayo Clin Proc 2004; 79: 541545.
  • 6
    Zakliczynski M, Nozynski J, Zakliczynska H, Rozentryt P, Zembala M. Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc 2003; 35: 23312332.
  • 7
    Montalbano M, Neff GW, Yamashiki N, Meyer D, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78: 264268.
  • 8
    Van Gelder T, Ter Meulen CG, Hene' R et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788791.
  • 9
    Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230238.
  • 10
    Ryan EA, Lakey JR, Paty BW et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 5: 2148.
  • 11
    Bryant T, Jackson JE. The radiographic appearances of non-specific small intestinal ulceration. Clin Radiol 2002; 57: 117122.
  • 12
    Calne RY, Collier DS, Lim S et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2: 227.
  • 13
    Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplantation Proceedings 2003; 35 (3 Suppl): 7S14S.
  • 14
    Van Gelder T, Ter Meulen CG, Hene' R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788791.
  • 15
    Van Gelder T, Ter Meulen CG, Hene' R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788791.
  • 16
    Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002; 6: 456464.
  • 17
    Aris RM, Maia DM, Neuringer IP et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus naïve lung transplant recipient. Am J Respir Crit Care Med 1996; 154: 17121717.
  • 18
    Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473.
  • 19
    Michael J, Greenstein J, Schechner R et al. Primary intestinal posttransplant T-cell lymphoma. Transplantation 2003; 27: 21312132.
  • 20
    Younes B, Ament M, McDiarmid S, Martin M, Vargas JH. The involvement of the gastrointestinal tract in postransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1999; 28: 380385.